Industry News
Pharmaceutical Industry News
Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market
Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market ntaylor Mon, 07/19/2021 - 06:26
Do We Need a Third Covid Shot?
The Delta variant has accelerated conversations about introducing booster doses of coronavirus vaccines.
Covid Vaccine Booster Shots Are Coming. Are they Needed?
Boosters may make it to market whether they are critical for vaccinated people or not.
Eli Lilly opens Olympic Games with first corporate ad—and a reality check on the state of the U.S. health system
Eli Lilly opens Olympic Games with first corporate ad—and a reality check on the state of the U.S. health system bbulik Fri, 07/16/2021 - 17:45
Lyme diagnostic maker Quidel pushes rapid testing in summer camp-focused campaign
Lyme diagnostic maker Quidel pushes rapid testing in summer camp-focused campaign bbulik Fri, 07/16/2021 - 15:33
Kadmon’s Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease esagonowsky Fri, 07/16/2021 - 15:24
Johnson & Johnson takes to Twitter to expand its network of storytelling patients
Johnson & Johnson takes to Twitter to expand its network of storytelling patients bbulik Fri, 07/16/2021 - 14:36
Merck KGaA’s U.S. unit launches first-ever TV ad with MS drug Mavenclad in the spotlight
Merck KGaA’s U.S. unit launches first-ever TV ad with MS drug Mavenclad in the spotlight bbulik Fri, 07/16/2021 - 14:00
Bristol Myers Squibb’s Opdivo and Yervoy combo falls short in first-line squamous head and neck cancer
Bristol Myers Squibb's Opdivo and Yervoy combo falls short in first-line squamous head and neck cancer kdunleavy Fri, 07/16/2021 - 11:38
AbbVie, Lilly atopic dermatitis hopefuls hit with more delays as FDA’s JAK inhibitor holdups carry on
AbbVie, Lilly atopic dermatitis hopefuls hit with more delays as FDA's JAK inhibitor holdups carry on nhigginsdunn Fri, 07/16/2021 - 11:17
Alexion’s Ultomiris notches myasthenia gravis win amid quest for 3rd Soliris use
Alexion's Ultomiris notches myasthenia gravis win amid quest for 3rd Soliris use fkansteiner Fri, 07/16/2021 - 09:29
Budget proposal to allow Medicare to negotiate prices should ‘enrage’ seniors, PhRMA says
Budget proposal to allow Medicare to negotiate prices should 'enrage' seniors, PhRMA says kdunleavy Fri, 07/16/2021 - 09:13
From masking to vaccines, Ad Council corrals feds, brands and media into COVID-19 campaigns
From masking to vaccines, Ad Council corrals feds, brands and media into COVID-19 campaigns bbulik Fri, 07/16/2021 - 08:55
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer’s drug
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug nhigginsdunn Fri, 07/16/2021 - 01:30
Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead
Pfizer antes up $345M to settle long-running EpiPen antitrust claims as Viatris case moves ahead fkansteiner Thu, 07/15/2021 - 21:18
AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data
AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data esagonowsky Thu, 07/15/2021 - 16:36
Fierce Pharma Asia—Sinovac, Sinopharm to supply 500M vaccine doses to COVAX; 2 approvals for Seagen-Astellas’ Padcev
Fierce Pharma Asia—Sinovac, Sinopharm to supply 500M vaccine doses to COVAX; 2 approvals for Seagen-Astellas' Padcev kdunleavy Thu, 07/15/2021 - 15:36
Takeda, AbbVie, BMS, Sanofi, Lilly and others join growing tally of pharma’s July price hikes: report
Takeda, AbbVie, BMS, Sanofi, Lilly and others join growing tally of pharma's July price hikes: report nhigginsdunn Thu, 07/15/2021 - 11:25
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie’s launches win on value: report
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report fkansteiner Thu, 07/15/2021 - 11:22
Biogen’s blockbuster Tysabri loses a key patent in Europe, adding to company’s worries: analyst
Biogen's blockbuster Tysabri loses a key patent in Europe, adding to company's worries: analyst kdunleavy Thu, 07/15/2021 - 10:43